Longitudinal characterization of symptoms, healthcare resource utilization, and costs among people with thrombotic thrombocytopenic purpura compared with non-thrombotic thrombocytopenic purpura controls.
Shan XingMichael BullanoSarah A HaleTasneem LokhandwalaKathryn DeYoungSharanya MurtyPublished in: Journal of medical economics (2024)
TTP is associated with a substantial symptom burden and increased costs and HCRU during and up to almost a year after acute events, demonstrating the longitudinal burden of this disease.